by Anand Patadiya | Nov 5, 2024
Safety and tolerability to be determined at up to 5 study sites in the United States and Canada November 5, 2024 (Cambridge, MA) – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first...
by Anand Patadiya | Oct 2, 2024
by Anand Patadiya | Oct 2, 2024
BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...
by Anand Patadiya | Oct 2, 2024
Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...
by Anand Patadiya | Oct 2, 2024
BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra...
